Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Lack of Association Between the CYP1A1 Ile462Val Polymorphism and Endometrial Cancer Risk: a Meta-analysis

  • Published : 2012.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Any association between the CYP1A1 Ile462Val polymorphism and endometrial cancer risk remains inconclusive. For a more precise estimate, we performed the present meta-analysis. Methods: PUBMED, OVID and EMBASE were searched for the studies which met inclusion criteria. Data in all eligible studies were evaluated and extracted by two authors independently. The meta-analysis estimated pooled odds ratio (OR) with 95% confidence interval (CI) for endometrial cancer risk attributable to the CYP1A1 Ile462Val polymorphism. Results: A total of 7 studies were included in this meta-analysis. The results indicated no association between endometrial cancer risk and the CYP1A1 Ile462Val polymorphism (for Val vs Ile allele model [OR 1.09, 95% CI 0.73-1.62]; for Val.Val vs Ile.Ile genotype model [OR 1.54, 95% CI 0.56-4.23]; for (Ile.Val + Val.Val) vs Ile.Ile genotpye model [OR 1.08, 95% CI 0.71-1.63]; for Val.Val vs (Ile.Ile + Ile.Val) genotype model [OR 1.46, 95% CI 0.53-4.04]). Conclusions: This meta-analysis suggests that there is no association between endometrial cancer risk and the CYP1A1 Ile462Val polymorphism.

Keywords

References

  1. Ashton KA, Proietto A, Otton G, et al (2010). Polymorphisms in genes of the steroid hormone biosynthesis and metabolism pathways and endometrial cancer risk. Cancer Epidemiol, 34, 328-37. https://doi.org/10.1016/j.canep.2010.03.005
  2. Auersperg N, Edeson MI, Mok SC, et al (1998) The biology of ovarian cancer. Semin Oncol, 25, 281-304.
  3. Barrena Medel NI, Bansal S, Miller DS, et al (2009). Pharmacotherapy of endometrial cancer. Expert Opin Pharmacother, 10, 1939-51. https://doi.org/10.1517/14656560903061291
  4. Cochran WG (1954). The combination of estimates from different experiments. Biometrics, 10, 101-29. https://doi.org/10.2307/3001666
  5. Cosma G, Crofts F, Taioli E, et al (1993). Relationship between genotype and function of the human CYP1A1 gene. J Toxicol Environ Health, 40, 309-16. https://doi.org/10.1080/15287399309531796
  6. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  7. Doherty JA, Weiss NS, Freeman RJ, et al (2005). Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer.. Cancer Epidemiol Biomarkers Prev, 14, 357-66. https://doi.org/10.1158/1055-9965.EPI-04-0479
  8. Drakoulis N, Cascorbi I, Brockmoller J, et al (1994) Polymorphism in the human CYP 1 A 1gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3'- flanking region. Clin Invest, 72, 240-8.
  9. Egger M, Davey Smith G. Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  10. Elwood JM, Cole P, Rothman KJ, et al (1977). Epidemiology of endometrial cancer. J Natl Cancer Inst, 59, 1055-60. https://doi.org/10.1093/jnci/59.4.1055
  11. Esinler I, Aktasy D, Alikasifogluy M, et al (2006). CYP1A1 gene polymorphism and risk of endometrial hyperplasia and endometrial carcinoma. Int J Gynecol Cancer, 16, 1407-11. https://doi.org/10.1111/j.1525-1438.2006.00605.x
  12. Esteller M, Garcia A, Martinez-Palones JM, et al (1997). Germ line polymorphisms in cytochrome-P450 1A1 (C4887 CYP1A1) and methylenetetrahydrofolate reductase (MTHFR) genes and endometrial cancer susceptibility. Carcinogenesis, 18, 2307-11. https://doi.org/10.1093/carcin/18.12.2307
  13. Esteller M, Garcia A, Martinez-Palones JM, et al (1997). Susceptibility to endometrial cancer: influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci. Br J Cancer, 75, 1385-8. https://doi.org/10.1038/bjc.1997.235
  14. Fader AN, Arriba LN, Frasure HE, et al (2009). Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol, 114, 121-7 https://doi.org/10.1016/j.ygyno.2009.03.039
  15. Hayashi S, Watanabe J, Nakachi K, et al (1991). Genetic linkage of lung cancer-associated Msp1 polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P4501A1. J Biochem, 110, 407-11. https://doi.org/10.1093/oxfordjournals.jbchem.a123594
  16. Herrington CS (2001). What we could do now: molecular pathology of gynaecological cancer. Mol Pathol, 54, 222-4. https://doi.org/10.1136/mp.54.4.222
  17. Higgins JP, Thompson SE (2002). Quantifying heterogeneity in a metaanalysis. Stat Med, 21, 1539-58. https://doi.org/10.1002/sim.1186
  18. Hirata H, Hinoda Y, Okayama N, et al (2008). CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility. Cancer, 112, 1964-73. https://doi.org/10.1002/cncr.23392
  19. Kawajiri K, Nakachi K, Imai K, et al (1993). The CYP1A1 gene and cancer susceptibility. Crit Rev Oncol Hematol, 14, 77-7. https://doi.org/10.1016/1040-8428(93)90007-Q
  20. Key TJ, Pike MC (1988). The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer, 57, 205-12. https://doi.org/10.1038/bjc.1988.44
  21. Kiyohara C, Hirohata T, Inutsuka S (1996). The relationship between aryl hydrocarbon hydroxylase and polymorphisms of the CYP1A1 gene. Jpn J Cancer Res, 87, 18-24. https://doi.org/10.1111/j.1349-7006.1996.tb00194.x
  22. La Vecchia C, Decarli A, Fasoli M, et al (1986). Nutrition and diet in the etiology of endometrial cancer. Cancer, 57, 1248-53. https://doi.org/10.1002/1097-0142(19860315)57:6<1248::AID-CNCR2820570631>3.0.CO;2-V
  23. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  24. Martucci CP, Fishman J (1993). P450 enzymes of estrogen metabolism. Pharmacol Ther, 57, 237-57. https://doi.org/10.1016/0163-7258(93)90057-K
  25. McGrath M, Hankinson SE, De Vivo I (2007). Cytochrome P450 1A1, cigarette smoking, and risk of endometrial cancer (United States). Cancer Causes Control, 18, 1123-30. https://doi.org/10.1007/s10552-007-9051-3
  26. Petersen DD, McKinney CE, Ikeya K, et al (1991). Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP. Am J Hum Genet, 48, 720-5.
  27. Rebbeck TR, Troxel AB, Wang Y, et al (2006). Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. J Natl Cancer Inst, 98, 1311-20. https://doi.org/10.1093/jnci/djj360
  28. Schwarz D, Kisselev P, Schunck WH, et al (2000). Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics, 10, 519-30. https://doi.org/10.1097/00008571-200008000-00005
  29. Seremak-Mrozikiewicz A, Drews K, Semczuk A, et al (2005). CYP1A1 alleles in female genital cancers in the Polish population. Eur J Obstet Gynecol Reprod Biol, 118, 246-50. https://doi.org/10.1016/j.ejogrb.2004.06.036
  30. Sugawara T, Nomura E, Sagawa T, et al (2003). CYP1A1 polymorphism and risk of gynecological malignancy in Japan. Int J Gynecol Cancer, 13, 785-90. https://doi.org/10.1111/j.1525-1438.2003.13607.x
  31. Taioli E, Crofts F, Trachman J, et al (1995) Radical differences in CYP1A1 genotype and function. Toxicol Lett, 77, 357-62. https://doi.org/10.1016/0378-4274(95)03318-1
  32. Zhang ZY, Fasco MJ, Huang L, et al (1996). Characterization of purified human recombinant cytochrome P4501A1-Ile462 and -Val462: assessment of a role for the rare allele in carcinogenesis. Cancer Res, 56, 3926-33.
  33. Zintzaras E, Chatzoulis DZ, Karabatsas CH, et al (2005). The relationship between C677T methylenetetrahydrofolate reductase gene polymorphism and retinopathy in type 2 diabetes: a metaanalysis. J Hum Genet, 50, 267-75. https://doi.org/10.1007/s10038-005-0250-z

Cited by

  1. Meta-analysis of Association Studies of CYP1A1 Genetic Polymorphisms with Digestive Tract Cancers Susceptibility in Chinese vol.15, pp.11, 2014, https://doi.org/10.7314/APJCP.2014.15.11.4689
  2. Accuracy of Intraoperative Gross Examination of Myometrial Invasion in Stage I-II Endometrial Cancer vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7061
  3. Overexpression of Platelet-derived Growth Factor-D as a Poor Prognosticator in Endometrial Cancer vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3741
  4. The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update vol.89, pp.3, 2015, https://doi.org/10.1007/s00204-014-1448-7
  5. CYP1A1 MspI Polymorphism and Cervical Carcinoma Risk in the Multi-Ethnic Population of Malaysia: a Case-Control Study vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.57
  6. Association of 42 SNPs with genetic risk for cervical cancer: an extensive meta-analysis vol.16, pp.1, 2015, https://doi.org/10.1186/s12881-015-0168-z
  7. Risk factors for endometrial cancer: An umbrella review of the literature pp.00207136, 2019, https://doi.org/10.1002/ijc.31961